Cavanagh Bethany J 4
Research Summary
AI-generated summary
Beam (BEAM) SVP Finance Bethany Cavanagh Sells 3,242 Shares
What Happened
Bethany J. Cavanagh, SVP, Finance and Treasurer of Beam Therapeutics (BEAM), sold 3,242 shares of common stock in an open-market transaction on April 1, 2026 at $24.58 per share for proceeds of about $79,688. This was a sale (not a purchase) and appears to be a routine disposition to satisfy tax withholding obligations tied to vested restricted stock units.
Key Details
- Transaction date and price: Apr 1, 2026 — 3,242 shares sold at $24.58 each (total ≈ $79,688).
- Reason/footnote: Shares were automatically sold to cover tax withholding on RSU vestings (granted under the 2019 Equity Incentive Plan for vesting dates 3/31/2022, 3/31/2023, 3/31/2024 and 3/31/2025).
- Trading plan: Sales were effected under a non‑discretionary Rule 10b5-1 trading plan adopted Aug 9, 2024.
- Shares owned after transaction: Not specified in the provided filing summary.
- Filing timing: Form 4 was filed Apr 6, 2026 for an Apr 1 transaction (filed five days after the trade); Form 4s are typically due within two business days, so this filing appears later than the usual window.
Context
This sale was performed to cover tax withholding on vested RSUs and executed under a pre-established 10b5-1 plan, which is common for routine tax-related sales and does not by itself indicate a change in insider sentiment about the company.